We are live on ! Find out more

Elanco Animal Health

ELAN

Market cap $11.6B

23.31 USD

+0.14

0.6%

At close Updated Sep 14, 10:44 AM EDT

1 day

0.6%

5 days

-4.35%

1 month

-1.52%

3 months

-4.03%

6 months

-0.38%

Year to date

3.51%

1 year

25.05%

5 years

-29.19%

10 years

-35.25%

About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.

Employees: 9,900

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.3%

Neutral 57.7%

Negative 0%

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026.

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

INDIANAPOLIS, Sept. 10, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

The Motley Fool

Elanco Director Purchases 40,000 Shares for $936,000

The purchase was valued at $936,000. This investment increased the insider's direct equity position by 27%.

Elanco Director Purchases 40,000 Shares for $936,000

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

Elanco Animal Health: New Products To Support Growth

I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.

Elanco Animal Health: New Products To Support Growth

The Motley Fool

Director's Confidence Visible as Elanco Leader Buys 10,000 Shares

The director upped their stake by 10,000 shares. This purchase increased the insider's direct equity holdings by 10%.

Director's Confidence Visible as Elanco Leader Buys 10,000 Shares

Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, recommended Netflix, Inc. (NASDAQ:NFLX).

Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC's ‘Final Trades'

Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform

Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN's innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program and strong cash flow; net leverage is targeted below 3.0x by 2027.

Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform

Elanco Animal Health Q2 Earnings Call Highlights

Elanco Animal Health NYSE: ELAN reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth.

Elanco Animal Health Q2 Earnings Call Highlights

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also offers producers Negasunt® Powder (coumaphos, propoxur, and sulfanilamide topical powder) and Tanidil®, which received emergency authorizations earlier this year, as well as EPA-registered Catron™ IV.

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

See News Rankings

Price charts implemented using Lightweight Charts™